PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza

$259,613R43FY2022IPCDC

Serplus Technology, Llc, San Mateo CA

Investigators

Philip Pembertoncontact

View original record on NIH RePORTER →

PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza · GrantIndex